Histological Remission during Corticosteroid Therapy of Overlapping Nonalcoholic Steatohepatitis and Autoimmune Hepatitis: Case Report and Literature Review

Concurrence of nonalcoholic steatohepatitis (NASH) with autoimmune hepatitis (AIH) is a rare condition that is challenging to diagnosis, due to the relatively high prevalence of autoantibodies in NASH. It is also difficult to determine the most effective treatment as corticosteroids are likely to wo...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in gastroenterology 2011-09, Vol.5 (3), p.553-557
Main Authors: Fukuda, Shinichiroh, Komori, Atsumasa, Itoh, Masahiro, Mihara, Yumi, Hashimoto, Satoru, Bae, Sung Kwan, Nagaoka, Shinya, Abiru, Seigo, Yatsuhashi, Hiroshi, Ishibashi, Hiromi
Format: Article
Language:English
Subjects:
Autoimmune hepatitis
Corticosteroid therapy
Histological remission
Nonalcoholic steatohepatitis
Published: September 2011
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Concurrence of nonalcoholic steatohepatitis (NASH) with autoimmune hepatitis (AIH) is a rare condition that is challenging to diagnosis, due to the relatively high prevalence of autoantibodies in NASH. It is also difficult to determine the most effective treatment as corticosteroids are likely to worsen NASH despite being effective in the treatment of AIH. In this case report, we present a female diagnosed with NASH-AIH overlap with accompanying diabetes mellitus, who successfully achieved normalization of serum alanine aminotransferase levels following prednisolone therapy and weight loss. A follow-up liver biopsy performed 40 months after the initial diagnosis showed only minimal inflammatory infiltrates in the portal area without any NASH histology. Resolution of NASH, in conjunction with a reduction in hepatic fibrosis, might suggest that prednisolone itself does not aggravate steatohepatitis, but rather prevents disease progression. Appropriate immunosuppressive treatment may therefore be an important component of the optimum therapy for NASH-AIH overlap.
ISSN:1662-0631
1662-0631
DOI:10.1159/000332152